DanielleElyseAntin-OzerkisMD

Pulmonology • North Haven, CT

Critical Care Medicine

Associate Professor, Internal Medicine, Yale University School of Medicine

Join to view full profile

Dr. Antin-Ozerkis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Antin-Ozerkis' full profile

Already have an account?

Office
6 Devine Street
Winchester Center for Lung Disease
North Haven, CT 06473
Phone+1 203-495-2410

Fax+1 203-239-8239
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Perelman School of Medicine at the University of PennsylvaniaClass of 1999

Certifications & Licensure

CT State Medical License 2006 - 2024
PA State Medical License 2000 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Start of enrollment: 2009 Oct 01
Completed
Phase 3
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Start of enrollment: 2009 Oct 01
Terminated
Phase 3
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Completed
Phase 2
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis Start of enrollment: 2020 Nov 12
Recruiting
Phase 1, Phase 2
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2019 Jun 18
Terminated
Phase 3
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2020 Sep 30
Terminated
Phase 3
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Mar 19
Terminated
Phase 3
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Aug 30
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

14 citations
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extensio...
Ganesh Raghu, Mark J Hamblin, A Whitney Brown, Jeffrey A Golden, Lawrence A Ho, Marlies S Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E Antin-Ozerkis, Keith ...> ;Respiratory Research. 2022 May 21
An 84-Year-Old Physician With Progressive Dyspnea and Bilateral Upper Lobe Opacities
Zachary Harris, Danielle Antin-Ozerkis> ;Chest. 2021 May 1
22 citations
A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY: Learning From the Past, Looking to the Future.
Denyse D. Lutchmansingh, Melissa P. Knauert, Danielle Antin-Ozerkis, Geoffrey Chupp, Lauren Cohn, Charles S. Dela Cruz, Lauren E. Ferrante, Erica L. Herzog, Jonathan L...> ;Chest. 2021 Mar 1
249 citations
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomise...
Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown, Yoshikazu Inoue, Anand Devaraj, Luca Richeldi, Teng Moua, Bruno Crestani, Wim A. Wuyts, Susanne Stowasser, Manuel Qu...> ;The Lancet. Respiratory Medicine. 2020 May 1
2 citations
Thoracic Manifestations of Rheumatic Disease
Danielle Antin-Ozerkis, Kristin B. Highland> ;Clinics in Chest Medicine. 2019 Sep 1
9 citations
Connective Tissue Disease-Associated Interstitial Lung Disease: Evaluation and Management.
Danielle Antin-Ozerkis, Monique Hinchcliff> ;Clinics in Chest Medicine. 2019 Sep 1
59 citations
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Ganesh Raghu, Bernt van den Blink, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden, Lawrence A. Ho, Marlies S. Wijsenbeek, Martina Vasakova, Alberto Pesci, Daniel...> ;The Lancet. Respiratory Medicine. 2019 Aug 1
13 citations
Update in Pulmonary Fibrosis 2018.
Giacomo Sgalla, Tejaswini Kulkarni, Danielle Antin-Ozerkis, Victor J. Thannickal, Luca Richeldi> ;American Journal of Respiratory and Critical Care Medicine. 2019 Aug 1
3 citations
Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials
Wim A. Wuyts, Danielle Antin-Ozerkis, J. Terrill Huggins, Peter P. LaCamera, Paolo Spagnolo, Martina Vasakova, Marlies S. Wijsenbeek, Boris Polman, Klaus-Uwe Kirchgaes...> ;Respiratory Medicine. 2019 Apr 1
140 citations
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial
Ganesh Raghu, Bernt van den Blink, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden, Lawrence A. Ho, Marlies S. Wijsenbeek, Martina Vasakova, Alberto Pesci, Daniel...> ;JAMA. 2018 Jun 12
3 citations
An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
Mark H. Gotfried, Carlos E. Girod, Danielle Antin-Ozerkis, Tracy Burgess, John L. Stauffer, Klaus Uwe Kirchgaessler, Maria Padilla> ;Pulmonary Therapy. 2018 Apr 5
110 citations
Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis
Changwan Ryu, Huanxing Sun, Mridu Gulati, Jose D. Herazo-Maya, Yonglin Chen, Awo Osafo-Addo, Caitlin Brandsdorfer, Julia Winkler, Christina Blaul, Jaden Faunce, Hongyi...> ;American Journal of Respiratory and Critical Care Medicine. 2017 Dec 15
69 citations
Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.
Argyris Tzouvelekis, Jose D. Herazo-Maya, Martin D. Slade, Jen-Hwa Chu, Giuseppe DeIuliis, Changwan Ryu, Qin Li, Koji Sakamoto, Gabriel Ibarra, Hongyi Pan, Mridu Gulat...> ;Respirology. 2017 Apr 1
Interstitial lung disease: time to rethink the snapshot diagnosis?
Danielle Antin-Ozerkis, Martin Kolb> ;Thorax. 2016 Jan 1
33 citations
The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.
Joao A. de Andrade, Marvin I. Schwarz, Harold R. Collard, Tedryl Gentry-Bumpass, Thomas V. Colby, David A. Lynch, Robert J. Kaner, M. Schwarz, David A. Zisman, James E...> ;Chest. 2015 Oct 1
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Raghu G> ;The New England journal of medicine. 2014-05-18
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn ...> ;The New England journal of medicine. 2014-05-18
2 citations
Pulmonary complications of connective tissue disease.
Danielle Antin-Ozerkis, Jeffrey J. Swigris> ;Seminars in Respiratory and Critical Care Medicine. 2014 Mar 25
1 citations
Supportive care for patients with pulmonary complications of connective tissue disease.
Mridu Gulati, Danielle Antin-Ozerkis> ;Seminars in Respiratory and Critical Care Medicine. 2014 Mar 25
191 citations
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Ganesh Raghu, Rachel Million-Rousseau, Adele Morganti, Loïc Perchenet, Juergen Behr, Nicole S L Goh, Allan R. Glanville, Michael Musk, Peter Hopkins, Dale Lien, Christ...> ;The European Respiratory Journal. 2013 Dec 1
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ> ;The New England journal of medicine. 2012-05-20
29 citations
Interstitial Lung Disease in the Connective Tissue Diseases
Danielle Antin-Ozerkis, Ami N. Rubinowitz, Janine Evans, Robert J. Homer, Richard A. Matthay> ;Clinics in Chest Medicine. 2012 Mar 1
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, CAPACITY Study Group> ;Lancet (London, England). 2011-05-13
29 citations
Pulmonary Manifestations of Rheumatoid Arthritis
Danielle Antin-Ozerkis, Janine Evans, Ami N. Rubinowitz, Robert J. Homer, Richard A. Matthay> ;Clinics in Chest Medicine. 2010 Sep 1
174 citations
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.
Susan K. Mathai, Mridu Gulati, Xueyan Peng, Thomas Russell, Albert C. Shaw, Ami N. Rubinowitz, Lynne Murray, Jonathan M. Siner, Danielle Antin-Ozerkis, Ruth R. Montgom...> ;Laboratory Investigation; a Journal of Technical Methods and Pathology. 2010 Jun 1
Join now to see all

Press Mentions

2023 ‘Top Doctors’ List Features Over 250 Yale Medicine PhysiciansMay 3rd, 2023
Following Computational Predictions, Scientists Demonstrate That Cancer Drug Counters Pulmonary FibrosisSeptember 1st, 2022
Saracatinib as Effective, or Superior to Ofev, Esbriet in IPF Models: StudyAugust 30th, 2022
Join now to see all

Hospital Affiliations

Yale-New Haven HospitalNew Haven, Connecticut